

A Randomized Trial of Liposomal Prednisolone (LIPMAT) to Enhance Radiocephalic Fistula Maturation: A Pilot Study

Bram M. Voorzaat¹, K.E.A. van der Bogt^{2,3}, Taisiya Bezhaeva¹, Jan van Schaik², Daniel Eefting^{2,3}, Karien van der Putten⁴, Roos C. van Nieuwenhuizen⁵, Johannes O. Groeneveld⁶, Ellen K. Hoogeveen⁷, Irene M. van der Meer⁸, Randolph G. Stadius van Eps⁹, Liffert Vogt¹⁰, Laurens Huisman¹¹, Bas A.Th.F. Gabreëls¹², Henk Boom¹³, Cornelis A. Verburch¹⁴, Diederik Boon¹⁵, Josbert M. Metselaar^{16,17}, Marcel C. Weijmer⁶ and Joris I. Rotmans¹

¹Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands; ²Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; ³Department of Vascular Surgery, Haaglanden Medical Center, The Hague, The Netherlands; ⁴Department of Nephrology, Tergooi Hospital, Hilversum, The Netherlands; ⁵Department of Vascular Surgery, OLVG, Amsterdam, The Netherlands; ⁶Department of Nephrology, OLVG, Amsterdam, The Netherlands; ⁷Department of Nephrology, Jeroen Bosch Ziekenhuis, Hertogenbosch, The Netherlands; ⁸Department of Nephrology, Haga Hospital, The Hague, The Netherlands; ⁹Department of Vascular Surgery, Haga Hospital, The Hague, The Netherlands; ¹⁰Department of Nephrology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; ¹¹Department of Vascular Surgery, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; ¹²Department of Nephrology, Alrijne Hospital, Leiderdorp, The Netherlands; ¹³Department of Nephrology, Reinier de Graaf Hospital, Delft, The Netherlands; ¹⁴Department of Nephrology, Spaarne Hospital, Haarlem, The Netherlands; ¹⁵Department of Nephrology, Dijklander Hospital, Hoorn, The Netherlands; ¹⁶Management Team, Enceladus Pharmaceuticals, Naarden, The Netherlands; and ¹⁷Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, Germany

Correspondence: Joris I. Rotmans, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. E-mail: J.I.Rotmans@lumc.nl

Received 25 January 2020; revised 21 May 2020; accepted 29 May 2020; published online 5 June 2022

Kidney Int Rep (2020) ■, ■-■; <https://doi.org/10.1016/j.ekir.2020.05.030>

© 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Patients on maintenance hemodialysis (HD) require a reliable vascular access; however, only half of newly created radiocephalic arteriovenous fistulas (RCAVF) can be used for HD without additional procedures to promote maturation and up to 25% fail to provide adequate vascular access for HD.¹ The need for subsequent creation of upper arm arteriovenous fistulas (AVFs) and arteriovenous grafts may decrease if maturation can be improved. Currently, no pharmacological treatments have been proven to improve clinical maturation of AVFs.

Although the underlying pathophysiology of non-maturation is incompletely understood, impaired outward remodeling and neointimal hyperplasia in the venous outflow tract seem to contribute.² Studies in murine and porcine models of AVF failure revealed a pronounced inflammatory response in the venous outflow tract in the early phase after AVF surgery.³ Recent studies suggest that this inflammatory response impairs AVF maturation.⁴

Pegylated liposomes have emerged as an attractive tool to facilitate selective delivery of drugs to inflamed tissues with a highly permeable microvasculature, where liposomes are being phagocytized by macrophages. It has a potent and long-lasting anti-inflammatory effect at sites of inflammation, while minimizing exposure of noninflamed tissues. In a murine model of AVF failure, we have demonstrated that liposomal prednisolone inhibits inflammation of the juxta-anastomotic vein and improves outward remodeling of the venous outflow tract.⁵

We hypothesized that maturation of RCAVFs in humans can be improved by inhibition of juxta-anastomotic inflammation using liposomal prednisolone. In the Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation (LIPMAT) study, we aimed to assess if liposomal prednisolone improves maturation of RCAVFs and if it can be safely administered to patients with end-stage renal disease. The design of this multicenter randomized




Figure 1. Study flow chart.

placebo-controlled trial has been reported earlier in detail,⁶ and methods are available in the [Supplementary Materials](#).

RESULTS

Study Population

From April 2016 through May 2018, 109 patients were planned for RCAVF creation and assessed for study eligibility. A total of 64 patients were excluded for known exclusion criteria from their medical history ($n = 24$), not consenting to study participation ($n = 34$), or late referral ($n = 6$,

[Figure 1](#)). Of the remaining 45 patients who provided informed consent, 32 were randomized ([Table 1](#)). Reasons for dropout are shown in [Figure 1](#). After randomization, but before treatment, 2 patients experienced clinical events constituting exclusion criteria. The remaining 30 patients received the study treatment. The trial was stopped prematurely in May 2018 because of slow enrollment.

End Points

The primary end point was assessed in 29 patients. The distal cephalic diameter was 3.9 mm (95% confidence

Table 1. Baseline characteristics of 29 patients in the LIPMAT study by treatment group

Baseline characteristics	Placebo (n = 13)	Liposomal prednisolone (n = 16)	Total (n = 29)
Age, yr	70 ± 8.5	65 ± 12	67 ± 11
Gender			
Female	5 (38)	1 (6)	6 (21)
Male	8 (62)	15 (94)	23 (79)
Race			
Caucasian	11 (85)	13 (81)	24 (83)
Hindustani Surinamese	1 (8)	2 (13)	3 (10)
Moroccan	0 (0)	1 (6)	1 (3)
Asian	1 (8)	0 (0)	1 (3)
Cause of renal failure			
Diabetes mellitus	4 (31)	6 (38)	10 (35)
Renal vascular disease	5 (39)	4 (25)	9 (31)
Glomerulonephritis	3 (23)	2 (13)	5 (17)
Interstitial nephropathy	1 (8)	2 (13)	3 (10)
Cystic kidney disease	0 (0)	2 (13)	2 (7)
Comorbidities			
Diabetes mellitus	7 (54)	7 (44)	14 (48)
Coronary artery disease	6 (46)	4 (25)	10 (35)
Peripheral artery disease	4 (31)	3 (19)	7 (24)
Cerebrovascular disease	5 (39)	4 (25)	9 (31)
Medication			
ACE inhibitor	1 (8)	6 (38)	7 (24)
Angiotensin 2 receptor blocker	8 (62)	5 (31)	13 (45)
Loop diuretic	8 (62)	9 (56)	17 (59)
Aldosterone receptor antagonist	0 (0)	1 (6)	1 (3)
Beta blocker	10 (77)	8 (50)	18 (62)
Calcium channel blocker	8 (62)	11 (69)	19 (66)
Platelet inhibitor	4 (31)	10 (63)	14 (48)
Anticoagulant	2 (15)	3 (19)	5 (17)
Vitamin D	12 (92)	13 (81)	25 (86)

ACE, angiotensin-converting enzyme; LIPMAT, Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation.

Data are reported as mean ± SD or n (%).

interval, 2.7–5.8 mm) in the placebo group and 3.7 mm (95% confidence interval, 3.0–5.3 mm) in the treatment group ($P = 0.88$). No significant results were observed for secondary end points (Table 2).

Functional Outcomes

At the time of assessment of the functional outcomes, 54% of AVFs in the placebo arm and 69% in the liposomal prednisolone arm were successfully used for HD ($P = 0.41$). Seven patients (44%) in the liposomal prednisolone arm and 4 patients (31%) in the placebo group underwent an endovascular or surgical procedure to achieve RCAFV maturation. During follow-up, in the placebo and liposomal prednisolone groups, respectively 23% and 13% of RCAFVs had failed ($P = 0.45$). The functional outcome could not be determined for 6 patients, because of loss to follow-up (2 patients who moved abroad) or not initiating HD (Table 3).

Table 2. Effect of liposomal prednisolone on primary and secondary end points in 29 patients in the LIPMAT study

End points	Placebo median (IQR)	Liposomal prednisolone median (IQR)	P (Mann-Whitney U)
6 weeks			
Cephalic vein			
Juxta-anastomotic diameter, mm	3.9 (2.7–5.8)	3.7 (3.0–5.3)	0.88
Elbow diameter, mm	5.5 (4.7–6.7)	5.0 (4.0–6.1)	0.47
Mid upper arm diameter, mm	4.0 (2.3–5.3)	4.8 (4.1–5.4)	0.22
Radial artery			
Juxta-anastomotic diameter, mm	3.6 (2.9–4.2)	3.6 (3.0–4.0)	0.83
Flow, ml/min	456 (277–688)	406 (300–772)	0.81
Brachial artery			
Flow, ml/min	523 (342–985)	550 (417–1201)	0.79
3 months			
Cephalic vein			
Juxta-anastomotic diameter, mm	4.2 (2.3–6.1)	4.9 (3.9–5.8)	0.43
Elbow diameter, mm	6.2 (4.7–6.9)	5.7 (4.4–6.3)	0.35
Mid upper arm diameter, mm	5.8 (2.8–4.5)	5.7 (3.6–6.2)	0.83
Radial artery			
Juxta-anastomotic diameter, mm	4.0 (2.1–5.0)	3.6 (3.0–4.6)	1.00
Flow, ml/min	546 (110–1037)	560 (334–970)	0.65
Brachial artery			
Flow, ml/min	800 (434–1485)	798 (479–1019)	0.60

IQR, inter quartile range; LIPMAT, Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation.

Safety

No infusion reactions were observed except for 1 subject in the liposomal prednisolone arm who was known to have symptoms of orthostatic hypotension, and experienced mild dizziness without hypotension on postural change during the infusion. The incidence of symptoms related to progressive renal failure and cardiovascular events was similar in both treatment arms (Table 4).

Infections

In the liposomal prednisolone arm, 5 infections were observed in the 3 months of follow-up. One subject was treated with antibiotics due to erythema in the AVF arm, without fever or systemic symptoms. One subject experienced 2 episodes of mild rhinosinusitis that resolved without specific treatment. One subject died 72 days after AVF surgery, because of progressive fluid overload, complicated by septicemia from a possible catheter-related infection or pneumonia. In the placebo group, 1 subject experienced a dental abscess 3 months after AVF surgery.

DISCUSSION

In the LIPMAT study, we evaluated if liposomal prednisolone improves maturation of RCAFVs. The trial

Table 3. Effect of liposomal prednisolone on functional outcomes of RCAVF in 29 patients in the LIPMAT study

Functional outcome	Placebo (n = 13)	Liposomal prednisolone (n = 16)
AVF used		
Without procedures to improve maturation	3 (23)	4 (25)
With procedures to improve maturation	4 (31)	7 (44)
AVF not used		
Failed due to nonmaturation	3 (23)	2 (13)
Kidney transplantation	0 (0)	1 (6)
Did not reach ESRD	1 (8)	1 (6)
Deceased before ESRD	0 (0)	1 (6)
Loss to follow-up	2 (16)	0 (0)

Values are n (%).

AVF, arteriovenous fistula; ESRD, end-stage renal disease; LIPMAT, Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation.

was terminated because of slow enrollment after inclusion of 30 of the 80 subjects initially aimed for. We present the study to investigate feasibility and to report preliminary outcomes. Liposomal prednisolone was safe and well-tolerated by patients with end-stage renal disease. No severe infusion reactions were observed and no severe infections were observed within the expected duration of effect of liposomal prednisolone. Liposomal prednisolone did not result in improved RCAVF maturation as measured by ultrasound at 6 weeks and 3 months after surgery. The 62% successful cannulation rate observed in the LIPMAT study was comparable to previous studies on functional AVF maturation.^{1,7} Although the nonsignificant result may be a mere result of a lack of power due to the small sample size, also no trend toward any difference between the treatment and control group was observed. Apart from a lack of statistical power, several factors might explain the lack of therapeutic efficacy of liposomal prednisolone to improve AVF maturation. First, the local concentration of liposomal prednisolone in the vessel wall of the AVF might not have been sufficient to exert a strong anti-inflammatory effect. The local accumulation of liposomal prednisolone could not be examined, as the AVFs could not be sacrificed for examination. In addition, no approved formulation of the compound was available to trace the liposomes in vivo in humans. Second, the inflammatory response in the RCAVF might have been too limited to induce significant local vascular accumulation of the liposomes. Previous clinical studies revealed substantial localization of liposomal prednisolone in the atherosclerotic arterial wall.⁸ As the prevalence of atherosclerosis was high in the LIPMAT subjects (Table 1), a significant proportion of liposomal prednisolone may therefore have accumulated in nontarget vessel walls instead of the AVF vein. In future studies, tissue samples of AVFs that failed early may be acquired

Table 4. Adverse events reported in the LIPMAT study

Adverse events	Placebo (n = 13)	Liposomal prednisolone (n = 16)
AVF-related events		
Angiography/angioplasty	3	6
Revision surgery	1	0
Coiling or ligation of collateral veins	1	2
Hematoma or bleeding	2	1
New AVF within 3 months	1	1
Nerve damage	1	0
Edema	1	0
Infusion-related events		
Orthostatic symptoms (no hypotension)	0	1
Renal and metabolic		
Fluid overload	3	2
Gout	1	0
Uremia (worsening)	1	0
Anemia (worsening)	1	1
Cardiovascular		
Atrial fibrillation/flutter	2	4
Myocardial infarction	1	2
Angina pectoris (worsening)	0	1
Intermittent claudication (worsening)	1	0
Infectious		
AVF site infection	0	1
Cellulitis (non-AVF site)	0	1
Upper airway infection including rhinosinusitis	0	2
Septicemia	0	1
Dental	1	0
Other		
Accidental injury	3	2
Fatigue and sleep disorders	4	4
Liver enzyme abnormalities	2	2
Hyperthyroidism	0	1
Hair loss	1	0
Intoxication	0	1
Aspecific thoracic pain	0	1
Constipation	0	1
Sunburn	0	1
Melanoma	1	0
Gastric pain	0	1
Hematoma non-AVF site	0	1
Urinary catheter placement	0	1

Myocardial infarction includes non-ST-elevation myocardial infarction.

AVF, arteriovenous fistula; LIPMAT, Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation.

during surgical revisions and analyzed for liposomal prednisolone content.

The extent and timing of venous inflammation after AVF surgery in humans is not fully known. To avoid potential detrimental effects on wound healing, liposomal prednisolone was not administered before surgery. As most of outward remodeling of AVFs has been shown to occur within the first 4 weeks after surgery,⁹ we aimed to cover this interval by administering the drug at day 1 and 15 after surgery. This might have been too short, with significant inflammation persisting at 4 weeks after surgery.

CONCLUSION AND FURTHER DIRECTIONS

The LIPMAT study was the first to study an anti-inflammatory strategy to improve AVF maturation in humans. We could not demonstrate a clinically significant impact on RCAVF maturation. Future studies are needed to elucidate the role of inflammation in AVF maturation and the clinical promise of liposomal formulations of anti-inflammatory drugs to promote AVF maturation.

ACKNOWLEDGMENTS

LIPMAT Study Group

Leiden University Medical Center: Bram M. Voorzaat, MD, Jan van Schaik, MD, Koen E.A. van der Bogt, MD, PhD, Joris I. Rotmans, MD, PhD. Academic University: Liffert Vogt, MD, PhD, Laurens Huisman, MD. Alrijne Hospital: Bas A.Th.F. Gabreëls, MD, PhD. Jeroen Bosch Hospital: Ellen K. Hoogeveen, MD, PhD. Haaglanden Medical Center: Daniël Eefting, MD, PhD. Haga Hospital: Irene M. van der Meer, MD, PhD, Randolph G. Stadius van Eps, MD, PhD. OLVG: Marcel C. Weijmer, MD, PhD, Johannes O. Groeneveld, MD, Roos C. van Nieuwenhuizen, MD. Reinier de Graaf Hospital: Henk Boom, MD, PhD. Spaarne Hospital: Cornelis A. Verburgh, MD, PhD. Tergooi Hospital: Karien van der Putten, MD, PhD, Niek A. Koedam, MD, PhD. Dijklander Hospital: D. Boon, MD, PhD.

Data Safety Monitoring Board

Erasmus Medical Center: H.J.M. Verhagen, MD, PhD (Chair). University Medical Center Groningen: M.H. de Borst, MD, PhD. Leiden University Medical Center: S. le Cessie, PhD (statistician).

Registration

The study was registered at [ClinicalTrials.gov](https://clinicaltrials.gov), identifier NCT02495662.

This study has received financial support from an unrestricted grant from Enceladus Pharmaceuticals B.V.

DISCLOSURE

EKH is a member of the Guideline Committee of the Dutch Federation of Nephrology. All the other authors declared no competing interests.

JMM is affiliated with Enceladus Pharmaceuticals which contributed financially to the work reported in this publication.

SUPPLEMENTARY MATERIAL

[Supplementary File \(PDF\)](#)

Supplementary Inclusion and Exclusion Criteria.

Supplementary Methods.

Supplementary References.

REFERENCES

1. Voorzaat BM, van der Bogt KEAA, Janmaat CJ, et al. Arteriovenous fistula maturation failure in a large cohort of hemodialysis patients in the Netherlands. *World J Surg.* 2018;42:1895–1903.
2. Rothuizen TC, Wong C, Quax PHA, et al. Arteriovenous access failure: more than just intimal hyperplasia? *Nephrol Dial Transplant.* 2013;28:1085–1092.
3. Dundon BK, Torpey K, Nelson AJ, et al. The deleterious effects of arteriovenous fistula-creation on the cardiovascular system: a longitudinal magnetic resonance imaging study. *Int J Nephrol Renovasc Dis.* 2014;7:337–345.
4. Bezhaeva T, de Vries MR, Geelhoed WJ, et al. Relaxin receptor deficiency promotes vascular inflammation and impairs outward remodeling in arteriovenous fistulas. *FASEB J.* 2018;32:6293–6304.
5. Wong C, Bezhaeva T, Rothuizen TC, et al. Liposomal prednisolone inhibits vascular inflammation and enhances venous outward remodeling in a murine arteriovenous fistula model. *Sci Rep.* 2016;6:30439.
6. Voorzaat BM, van Schaik J, van der Bogt KEA, et al. Improvement of radiocephalic fistula maturation: rationale and design of the Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation (LIPMAT) study—a randomized controlled trial. *J Vasc Access.* 2017;18(suppl 1):S114–S117.
7. Bleyer AJ, Scavo VA, Wilson SE, et al. A randomized trial of vonapanitase (PATENCY-1) to promote radiocephalic fistula patency and use for hemodialysis. *J Vasc Surg.* 2019;69:507–515.
8. der Valk FM van, van Wijk DF, Lobatto ME, et al. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. *Nano-medicine.* 2015;11:1039–1046.
9. Robbin ML, Greene T, Cheung AK, et al. Arteriovenous fistula development in the first 6 weeks after creation. *Radiology.* 2016;279:620–629.